Xencor (NASDAQ:XNCR) had its price target raised by Canaccord Genuity from $36.00 to $38.00 in a research report report published on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
XNCR has been the subject of several other reports. BidaskClub upgraded Xencor from a buy rating to a strong-buy rating in a report on Friday, March 9th. Wedbush increased their target price on Xencor from $38.00 to $39.00 and gave the company an outperform rating in a report on Monday, March 19th. Cantor Fitzgerald restated an overweight rating and set a $37.00 target price on shares of Xencor in a report on Thursday, March 1st. Leerink Swann reiterated an outperform rating and issued a $36.00 price objective on shares of Xencor in a report on Wednesday, March 28th. Finally, Nomura dropped their price objective on Xencor to $28.00 and set a neutral rating for the company in a report on Thursday, April 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Xencor presently has an average rating of Buy and a consensus price target of $35.29.
Shares of XNCR stock opened at $31.53 on Wednesday. The stock has a market cap of $1.66 billion, a P/E ratio of -30.03 and a beta of 1.51. Xencor has a 1-year low of $18.55 and a 1-year high of $34.63.
Xencor (NASDAQ:XNCR) last issued its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.16). Xencor had a negative net margin of 137.35% and a negative return on equity of 18.07%. equities analysts predict that Xencor will post -2.36 earnings per share for the current fiscal year.
In other Xencor news, insider Edgardo Baracchini, Jr. sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $30.89, for a total value of $1,235,600.00. Following the completion of the sale, the insider now owns 40,000 shares in the company, valued at approximately $1,235,600. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Paul A. Foster sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total value of $260,300.00. Following the completion of the sale, the insider now owns 12,419 shares of the company’s stock, valued at approximately $323,266.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,000 shares of company stock valued at $3,101,550. Company insiders own 4.03% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in XNCR. BVF Inc. IL purchased a new position in shares of Xencor in the 1st quarter valued at approximately $27,042,000. Artal Group S.A. lifted its stake in shares of Xencor by 200.0% in the 1st quarter. Artal Group S.A. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $8,994,000 after purchasing an additional 200,000 shares during the period. Redmile Group LLC lifted its stake in shares of Xencor by 12.5% in the 4th quarter. Redmile Group LLC now owns 1,350,894 shares of the biopharmaceutical company’s stock valued at $29,612,000 after purchasing an additional 150,600 shares during the period. ArrowMark Colorado Holdings LLC lifted its stake in shares of Xencor by 32.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 583,491 shares of the biopharmaceutical company’s stock valued at $12,790,000 after purchasing an additional 144,319 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Xencor by 75.2% in the 4th quarter. Deutsche Bank AG now owns 155,343 shares of the biopharmaceutical company’s stock valued at $3,402,000 after purchasing an additional 66,656 shares during the period. Institutional investors own 67.15% of the company’s stock.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.